ONCODESIGN Logo

ONCODESIGN

Developing precision oncology solutions for resistant and metastatic cancers.

ALONC | PA

Overview

Corporate Details

ISIN(s):
FR0011766229
LEI:
9695004HPDBVG72O8851
Country:
France
Address:
20 RUE JEAN MAZEN, 21000 DIJON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oncodesign Precision Medicine (OPM) is a biotechnology company dedicated to developing innovative therapeutic and diagnostic solutions. The company's core mission is to address therapeutic resistance and metastasis in cancer through a precision medicine approach. Utilizing a patient-centric, translational model, OPM focuses on discovering and advancing treatments for patients with resistant and metastatic cancers. The company collaborates with clinicians, service providers, and experts to guide its research and development investments towards meeting significant unmet medical needs in oncology.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-12-13 14:25
Delisting Announcement
Communiqués publiés en période d'offre publique d'acquisition / OPA Autres comm…
French 150.7 KB
2022-12-13 11:17
Major Shareholding Notification
Franchissement de seuils
French 209.0 KB
2022-11-24 08:00
M&A Activity
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 145.1 KB
2022-11-23 17:37
Prospectus
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 724.9 KB
2022-11-23 17:36
M&A Activity
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 2.3 MB
2022-11-08 16:38
M&A Activity
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 2.2 MB
2022-11-08 15:54
Delisting Announcement
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 231.6 KB
2022-11-02 17:28
Prospectus
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 1.0 MB
2022-11-02 17:25
Prospectus
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 506.0 KB
2022-10-26 11:17
Major Shareholding Notification
Franchissement de seuil
French 198.3 KB
2022-10-26 11:16
Major Shareholding Notification
Franchissement de seuils
French 206.0 KB
2022-10-19 08:00
M&A Activity
Inside Information / Operations of the issuer (acquisitions, sales...)
English 340.5 KB
2022-10-19 08:00
M&A Activity
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
French 390.8 KB
2022-10-04 18:00
Delisting Announcement
Inside Information / Other news releases
English 268.6 KB
2022-10-04 18:00
Delisting Announcement
Informations privilégiées / Autres communiqués
French 273.9 KB

Automate Your Workflow. Get a real-time feed of all ONCODESIGN filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ONCODESIGN

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ONCODESIGN via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CEL SCI CORP Logo
Develops immunotherapies for cancer, autoimmune, and infectious diseases.
United States of America
CVM
Celularity Inc Logo
Develops off-the-shelf cell therapies from placentas for cancer and aging-related diseases.
United States of America
CELU
Centessa Pharmaceuticals plc Logo
Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.
United States of America
CNTA
CERO THERAPEUTICS HOLDINGS, INC. Logo
Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.
United States of America
CERO
CervoMed Inc. Logo
Developing CNS therapeutics for neurodegenerative diseases like dementia with Lewy bodies.
United States of America
CRVO
Cessatech A/S Logo
Develops a non-invasive nasal spray for acute pain relief in children during medical procedures.
Denmark
CESSA
CG Invites Co., Ltd. Logo
Biopharma advancing precision medicine with drugs, mRNA vaccines, and digital therapeutics.
South Korea
083790
CG Oncology, Inc. Logo
Developing bladder-sparing oncolytic immunotherapies for patients with bladder cancer.
United States of America
CGON
CHA Vaccine Research Institute Logo
Develops vaccines and immunotherapies for infectious diseases and cancer using proprietary platforms.
South Korea
261780
Manufactures veterinary medicines and feed additives for livestock, aquatic animals, and pets.
South Korea
052670

Talk to a Data Expert

Have a question? We'll get back to you promptly.